A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This was a multicenter study evaluating the efficacy and safety of
ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with ribavirin (RBV) for 12
weeks in treatment naïve and pegylated-interferon alfa-2a or alfa-2b (pegIFN)/RBV
treatment-experienced, cirrhotic HCV genotype 1b-infected adults.